

G
CCA ACA CTT-3' (SEQ ID NO:2) for the Gln-41 substitution, and 5'-GTT GAA ATT GCA CTG CTC AAA CTT CCA-3' (SEQ ID NO:3) for the Gln-44 mutation. Successful mutagenesis was confirmed by sequencing using standard methods.

In the Claims

G
Please cancel claim 33.

G
Please rewrite the claims as shown below.

4. (Amended) A method for determining regression, progression or onset of a diabetic condition characterized by abnormal levels of glycated protein comprising;
G
obtaining a level of the amount of K41-glycated CD59 from a sample obtained from a subject, and
comparing the level to a control as a determination of regression, progression or onset of the condition, wherein the level is obtained using an antibody or antigen-binding fragment thereof.

31. (Amended) The method of claim 4, wherein the antibody or antigen-binding fragment thereof binds specifically to K41-glycated CD59.
G

32. (Amended) The method of claim 4, wherein the antibody or antigen-binding fragment thereof is detectably labeled.

34. (Amended) The method of claim 4, wherein the antibody is a monoclonal antibody.

35. (Amended) The method of claim 4, wherein the antibody is a polyclonal antibody.

G
36. (Amended) The method of claim 4, wherein the level is obtained using two antibodies or antigen-binding fragments thereof, a first antibody or antigen-binding fragment thereof that binds

both glycated and nonglycated CD59 and a second antibody or antigen-binding fragment thereof that binds only one of a glycated K41 and a nonglycated K41.

37. (Amended) The method of claim 36, wherein one or more of the first and second antibody or antigen-binding fragment thereof is detectably labeled.

39. (Amended) The method of claim 36, wherein one or more of the first and second antibodies is a monoclonal antibody.

40. (Amended) The method of claim 36, wherein one or more of the first and second antibodies is a polyclonal antibody.

C2
Please add the following new claim:

41. (New) The method of claim 4, wherein the sample is a tissue sample.

Remarks

The specification was amended to correct erroneous sequence designations. In the application as filed, SEQ ID NO:2 and SEQ ID NO:3 were inadvertently identified as SEQ ID NO:1 and SEQ ID NO:2 respectively. Claim 4 was amended to specify that the condition characterized by abnormal levels of glycated protein with the methods of the invention, is a diabetic condition. Support for this amendment can be found at in the specification at least on page 12 line 32 through page 13 line 9. Claim 4 was amended to specify that an agent is an antibody or antigen-binding fragment thereof. Consistent with this amendment to claim 4, claim 33 was cancelled and claims 31, 32, and 34-40 were amended to reflect the inclusion in claim 4 of an antibody or antigen-binding fragment thereof as the agent. A new claim 41 was added to identify "tissue" as a type of sample. Support is found at least at page 12, lines 25-26 of the specification. No new matter has been added.

Rejections Under 35 U.S.C. §112, First Paragraph